Compare MOBI & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOBI | ABEO |
|---|---|---|
| Founded | N/A | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.0M | 399.5M |
| IPO Year | 2026 | 2005 |
| Metric | MOBI | ABEO |
|---|---|---|
| Price | $10.75 | $5.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 154.9K | ★ 1.1M |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $10.01 | $4.00 |
| 52 Week High | $15.19 | $7.65 |
| Indicator | MOBI | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 39.10 | 33.09 |
| Support Level | N/A | $5.23 |
| Resistance Level | $12.28 | $5.55 |
| Average True Range (ATR) | 0.84 | 0.21 |
| MACD | -0.12 | -0.05 |
| Stochastic Oscillator | 6.02 | 11.88 |
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.